PT  - JOURNAL ARTICLE
AU  - Darst, Burcu F.
AU  - Shen, Jiayi
AU  - Madduri, Ravi K.
AU  - Rodriguez, Alexis A.
AU  - Xiao, Yukai
AU  - Sheng, Xin
AU  - Saunders, Edward J.
AU  - Dadaev, Tokhir
AU  - Brook, Mark N.
AU  - Hoffmann, Thomas J.
AU  - Muir, Kenneth
AU  - Wan, Peggy
AU  - Marchand, Loic Le
AU  - Wilkens, Lynne
AU  - Wang, Ying
AU  - Schleutker, Johanna
AU  - MacInnis, Robert J.
AU  - Cybulski, Cezary
AU  - Neal, David E.
AU  - G. Nordestgaard, Børge
AU  - Nielsen, Sune F.
AU  - Batra, Jyotsna
AU  - Clements, Judith A.
AU - Australian Prostate Cancer BioResource
AU  - Grönberg, Henrik
AU  - Pashayan, Nora
AU  - Travis, Ruth C.
AU  - Park, Jong Y.
AU  - Albanes, Demetrius
AU  - Weinstein, Stephanie
AU  - Mucci, Lorelei A.
AU  - Hunter, David J.
AU  - Penney, Kathryn L.
AU  - Tangen, Catherine M.
AU  - Hamilton, Robert J.
AU  - Parent, Marie-Élise
AU  - Stanford, Janet L.
AU  - Koutros, Stella
AU  - Wolk, Alicja
AU  - Sørensen, Karina D.
AU  - Blot, William J.
AU  - Yeboah, Edward D.
AU  - Mensah, James E.
AU  - Lu, Yong-Jie
AU  - Schaid, Daniel J.
AU  - Thibodeau, Stephen N.
AU  - West, Catharine M.
AU  - Maier, Christiane
AU  - Kibel, Adam S.
AU  - Cancel-Tassin, Géraldine
AU  - Menegaux, Florence
AU  - John, Esther M.
AU  - Grindedal, Eli Marie
AU  - Khaw, Kay-Tee
AU  - Ingles, Sue A.
AU  - Vega, Ana
AU  - Rosenstein, Barry S.
AU  - Teixeira, Manuel R.
AU - NC-LA PCaP Investigators
AU  - Kogevinas, Manolis
AU  - Cannon-Albright, Lisa
AU  - Huff, Chad
AU  - Multigner, Luc
AU  - Kaneva, Radka
AU  - Leach, Robin J.
AU  - Brenner, Hermann
AU  - Hsing, Ann W.
AU  - Kittles, Rick A.
AU  - Murphy, Adam B.
AU  - Logothetis, Christopher J.
AU  - Neuhausen, Susan L.
AU  - Isaacs, William B.
AU  - Nemesure, Barbara
AU  - Hennis, Anselm J.
AU  - Carpten, John
AU  - Pandha, Hardev
AU  - De Ruyck, Kim
AU  - Xu, Jianfeng
AU  - Razack, Azad
AU  - Teo, Soo-Hwang
AU - Canary PASS Investigators
AU  - Newcomb, Lisa F.
AU  - Fowke, Jay H.
AU  - Neslund-Dudas, Christine
AU  - Rybicki, Benjamin A.
AU  - Gamulin, Marija
AU  - Usmani, Nawaid
AU  - Claessens, Frank
AU  - Gago-Dominguez, Manuela
AU  - Castelao, Jose Esteban
AU  - Townsend, Paul A.
AU  - Crawford, Dana C.
AU  - Petrovics, Gyorgy
AU  - Casey, Graham
AU  - Roobol, Monique J.
AU  - Hu, Jennifer F.
AU  - Berndt, Sonja I.
AU  - Van Den Eeden, Stephen K.
AU  - Easton, Douglas F.
AU  - Chanock, Stephen J.
AU  - Cook, Michael B.
AU  - Wiklund, Fredrik
AU  - Witte, John S.
AU  - Eeles, Rosalind A.
AU  - Kote-Jarai, Zsofia
AU  - Watya, Stephen
AU  - Gaziano, John M.
AU  - Justice, Amy C.
AU  - Conti, David V.
AU  - Haiman, Christopher A.
TI  - Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry
AID  - 10.1101/2023.05.12.23289860
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.05.12.23289860
4099  - http://medrxiv.org/content/early/2023/05/15/2023.05.12.23289860.short
4100  - http://medrxiv.org/content/early/2023/05/15/2023.05.12.23289860.full
AB  - Genome-wide polygenic risk scores (GW-PRS) have been reported to have better predictive ability than PRS based on genome-wide significance thresholds across numerous traits. We compared the predictive ability of several GW-PRS approaches to a recently developed PRS of 269 established prostate cancer risk variants from multi-ancestry GWAS and fine-mapping studies (PRS269). GW-PRS models were trained using a large and diverse prostate cancer GWAS of 107,247 cases and 127,006 controls used to develop the multi-ancestry PRS269. Resulting models were independently tested in 1,586 cases and 1,047 controls of African ancestry from the California/Uganda Study and 8,046 cases and 191,825 controls of European ancestry from the UK Biobank and further validated in 13,643 cases and 210,214 controls of European ancestry and 6,353 cases and 53,362 controls of African ancestry from the Million Veteran Program. In the testing data, the best performing GW-PRS approach had AUCs of 0.656 (95% CI=0.635-0.677) in African and 0.844 (95% CI=0.840-0.848) in European ancestry men and corresponding prostate cancer OR of 1.83 (95% CI=1.67-2.00) and 2.19 (95% CI=2.14-2.25), respectively, for each SD unit increase in the GW-PRS. However, compared to the GW-PRS, in African and European ancestry men, the PRS269 had larger or similar AUCs (AUC=0.679, 95% CI=0.659-0.700 and AUC=0.845, 95% CI=0.841-0.849, respectively) and comparable prostate cancer OR (OR=2.05, 95% CI=1.87-2.26 and OR=2.21, 95% CI=2.16-2.26, respectively). Findings were similar in the validation data. This investigation suggests that current GW-PRS approaches may not improve the ability to predict prostate cancer risk compared to the multi-ancestry PRS269 constructed with fine-mapping.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Cancer Institute at the National Institutes of Health grant (grant numbers U19 CA214253 to C.A.H., R01 CA257328 to C.A.H., U19 CA148537 to C.A.H., R01 CA165862 to C.A.H., and R00 CA246063 to B.F.D.), the Prostate Cancer Foundation (grants 21YOUN11 to B.F.D. and 20CHAS03 to C.A.H.), an award from the Andy Hill Cancer Research Endowment Distinguished Researchers Program (B.F.D.), a Fred Hutch/University of Washington SPORE Career Enhancement Program award (BFD), and the Million Veteran Program-MVP017.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from all participants, and study protocols were approved by the Institutional Review Boards at each institute.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe summary statistics used in this investigation are available through dbGaP under accession code phs001120. 1000 Genomes Project data can be found online: https://www.internationalgenome.org/. UK Biobank data is available to researchers with approved applications.